DOP2021000027A - Compuestos de 2,6-diaminopiridina - Google Patents

Compuestos de 2,6-diaminopiridina

Info

Publication number
DOP2021000027A
DOP2021000027A DO2021000027A DO2021000027A DOP2021000027A DO P2021000027 A DOP2021000027 A DO P2021000027A DO 2021000027 A DO2021000027 A DO 2021000027A DO 2021000027 A DO2021000027 A DO 2021000027A DO P2021000027 A DOP2021000027 A DO P2021000027A
Authority
DO
Dominican Republic
Prior art keywords
compounds
formula
diaminopyridine compounds
diaminopyridine
compound
Prior art date
Application number
DO2021000027A
Other languages
English (en)
Inventor
Barrett Durham Timothy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2021000027A publication Critical patent/DOP2021000027A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula I: o una sal farmacéuticamente aceptable de este, y el uso de los compuestos de Fórmula I para el tratamiento de afecciones metabólicas, tales como la diabetes mellitus tipo 2, la insuficiencia cardíaca, la enfermedad renal diabética y la esteatohepatitis no alcohólica.
DO2021000027A 2018-09-04 2021-02-16 Compuestos de 2,6-diaminopiridina DOP2021000027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726520P 2018-09-04 2018-09-04
PCT/US2019/048788 WO2020051058A1 (en) 2018-09-04 2019-08-29 2,6-diamino pyridine compounds

Publications (1)

Publication Number Publication Date
DOP2021000027A true DOP2021000027A (es) 2021-03-15

Family

ID=67982138

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000027A DOP2021000027A (es) 2018-09-04 2021-02-16 Compuestos de 2,6-diaminopiridina

Country Status (26)

Country Link
US (1) US10781212B2 (es)
EP (1) EP3846809B1 (es)
JP (1) JP6813720B1 (es)
KR (1) KR102365535B1 (es)
CN (1) CN112601525B (es)
AR (1) AR117640A1 (es)
AU (1) AU2019334877B2 (es)
BR (1) BR112021001881A2 (es)
CA (1) CA3111725C (es)
CL (1) CL2021000528A1 (es)
CO (1) CO2021002768A2 (es)
CR (1) CR20210085A (es)
DO (1) DOP2021000027A (es)
EA (1) EA202190302A1 (es)
EC (1) ECSP21015267A (es)
IL (1) IL280598B2 (es)
JO (1) JOP20210039A1 (es)
MA (1) MA53547A (es)
MX (1) MX2021002472A (es)
PE (1) PE20211595A1 (es)
PH (1) PH12021550449A1 (es)
SG (1) SG11202101687TA (es)
TW (1) TWI714231B (es)
UA (1) UA124917C2 (es)
WO (1) WO2020051058A1 (es)
ZA (1) ZA202100700B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI750685B (zh) * 2019-06-17 2021-12-21 美商美國禮來大藥廠 二取代吡唑化合物
TWI764467B (zh) 2019-12-24 2022-05-11 大陸商南京明德新藥研發有限公司 具有khk抑制作用的化合物
CN111423420A (zh) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 作为己酮糖激酶抑制剂的并环化合物
KR20230158542A (ko) 2021-03-29 2023-11-20 길리애드 사이언시즈, 인코포레이티드 Khk 억제제
WO2023151473A1 (zh) * 2022-02-09 2023-08-17 上海研健新药研发有限公司 一种khk抑制剂,其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094709B1 (en) * 2006-09-20 2010-09-15 Eli Lilly And Company Thiazole pyrazolopyrimidines as crf1 receptor antagonists
TW201623286A (zh) * 2014-04-04 2016-07-01 賽諾菲公司 作為gpr119調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物
PT3154959T (pt) * 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka
UA121271C2 (uk) * 2015-12-29 2020-04-27 Пфайзер Інк. Заміщені 3-азабіцикло[3.1.0]гексани як інгібітори кетогексокінази

Also Published As

Publication number Publication date
CL2021000528A1 (es) 2021-07-30
WO2020051058A1 (en) 2020-03-12
JP2021506949A (ja) 2021-02-22
KR20210034082A (ko) 2021-03-29
JP6813720B1 (ja) 2021-01-13
JOP20210039A1 (ar) 2021-03-04
EP3846809A1 (en) 2021-07-14
TWI714231B (zh) 2020-12-21
PH12021550449A1 (en) 2021-09-27
AU2019334877A1 (en) 2021-03-11
SG11202101687TA (en) 2021-03-30
IL280598A (en) 2021-03-25
TW202026289A (zh) 2020-07-16
US20200071331A1 (en) 2020-03-05
US10781212B2 (en) 2020-09-22
AU2019334877B2 (en) 2022-07-28
MX2021002472A (es) 2021-04-29
BR112021001881A2 (pt) 2021-04-27
ZA202100700B (en) 2022-09-28
AR117640A1 (es) 2021-08-18
CA3111725C (en) 2022-12-13
MA53547A (fr) 2022-04-27
EA202190302A1 (ru) 2021-06-10
UA124917C2 (uk) 2021-12-08
ECSP21015267A (es) 2021-04-29
CA3111725A1 (en) 2020-03-12
IL280598B1 (en) 2023-10-01
CN112601525B (zh) 2023-11-10
PE20211595A1 (es) 2021-08-18
KR102365535B1 (ko) 2022-02-23
CO2021002768A2 (es) 2021-05-20
EP3846809B1 (en) 2023-12-13
IL280598B2 (en) 2024-02-01
CR20210085A (es) 2021-04-29
CN112601525A (zh) 2021-04-02

Similar Documents

Publication Publication Date Title
DOP2021000027A (es) Compuestos de 2,6-diaminopiridina
CL2021003342A1 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.
BR112021023923A2 (pt) Agonistas de receptor de peptídeo 1 similares a glucagon
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
PE20191243A1 (es) Nuevos derivados de fenilo
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2022017226A2 (es) Antagonistas del receptor de lpa y usos de los mismos
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
WO2014126944A3 (en) Inhibitors of the renal outer medullary potassium channel
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
JP2016508506A5 (es)
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
MX2017000635A (es) Inhibidores del canal de potasio medular externo renal.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
MX2017000634A (es) Inhibidores del canal de potasio medularmente externo renal.
AR113995A1 (es) Moduladores de molécula pequeña del domino de btb de keap1
AR099767A1 (es) Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
AR109895A1 (es) Compuestos cíclicos de péptido tirosina tirosina como moduladores de neuropéptido y receptores
AR119173A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
EA202192957A1 (ru) Дизамещенные пиразольные соединения в качестве ингибиторов кетогексокиназы
AR115865A2 (es) Compuestos terapéuticos